ATE414059T1 - Kristalline form des natriumsalzes von 5-chlor-2- methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid - Google Patents

Kristalline form des natriumsalzes von 5-chlor-2- methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid

Info

Publication number
ATE414059T1
ATE414059T1 AT05024254T AT05024254T ATE414059T1 AT E414059 T1 ATE414059 T1 AT E414059T1 AT 05024254 T AT05024254 T AT 05024254T AT 05024254 T AT05024254 T AT 05024254T AT E414059 T1 ATE414059 T1 AT E414059T1
Authority
AT
Austria
Prior art keywords
methoxy
bnzamide
methylaminothiocarbonylaminosulfonylphenyl
ethy
chlorine
Prior art date
Application number
AT05024254T
Other languages
English (en)
Inventor
Heinrich Christian Englert
Uwe Gerlach
Tobias Metzenthin
Harald Schneider
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE414059T1 publication Critical patent/ATE414059T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C07C335/42—Sulfonylthioureas; Sulfonylisothioureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05024254T 1999-04-16 2000-04-04 Kristalline form des natriumsalzes von 5-chlor-2- methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid ATE414059T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19917233A DE19917233A1 (de) 1999-04-16 1999-04-16 Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids

Publications (1)

Publication Number Publication Date
ATE414059T1 true ATE414059T1 (de) 2008-11-15

Family

ID=7904803

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05024254T ATE414059T1 (de) 1999-04-16 2000-04-04 Kristalline form des natriumsalzes von 5-chlor-2- methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid
AT00926805T ATE311364T1 (de) 1999-04-16 2000-04-04 Kristalline form 3 des natriumsalzes von 5-chlor- 2-methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00926805T ATE311364T1 (de) 1999-04-16 2000-04-04 Kristalline form 3 des natriumsalzes von 5-chlor- 2-methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid

Country Status (33)

Country Link
US (1) US6723751B1 (de)
EP (2) EP1637519B1 (de)
JP (1) JP4662640B2 (de)
KR (1) KR100700302B1 (de)
CN (1) CN1168712C (de)
AR (1) AR023479A1 (de)
AT (2) ATE414059T1 (de)
AU (1) AU773246B2 (de)
BR (1) BR0010658A (de)
CA (1) CA2370388C (de)
CZ (1) CZ302459B6 (de)
DE (3) DE19917233A1 (de)
DK (1) DK1173418T3 (de)
EE (1) EE04612B1 (de)
ES (1) ES2251996T3 (de)
HK (1) HK1046270B (de)
HR (1) HRP20010744B1 (de)
HU (1) HU229082B1 (de)
IL (2) IL145921A0 (de)
ME (1) MEP55708A (de)
MX (1) MXPA01010275A (de)
MY (1) MY122588A (de)
NO (1) NO327798B1 (de)
NZ (1) NZ514788A (de)
PL (1) PL203809B1 (de)
RS (1) RS50916B (de)
RU (1) RU2235089C2 (de)
SI (1) SI1173418T1 (de)
SK (1) SK287175B6 (de)
TR (2) TR200102993T2 (de)
TW (1) TWI276622B (de)
WO (1) WO2000063167A1 (de)
ZA (1) ZA200108400B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289507A1 (de) * 2003-03-17 2011-03-02 Japan Tobacco, Inc. Pharmazeutische CETP-Inhibitor-Zubereitungen
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2098069T3 (es) 1993-02-23 1997-04-16 Hoechst Ag Bencenosulfonil-ureas y -tioureas sustituidas, procedimiento para su preparacion y su utilizacion como agentes farmaceuticos.
DE19505397A1 (de) * 1995-02-17 1996-08-22 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CZ301165B6 (cs) * 1998-09-10 2009-11-25 Sanofi - Aventis Deutschland GmbH Použití benzensulfonyl(thio)mocovin pro lécení a profylaxi dysfunkcí autonomní nervové soustavy a použití benzensulfonyl(thio)mocovin v kombinaci s beta-receptorovými blokátory

Also Published As

Publication number Publication date
DE60024431T2 (de) 2006-07-27
EE200100532A (et) 2002-12-16
NZ514788A (en) 2003-03-28
EE04612B1 (et) 2006-04-17
KR100700302B1 (ko) 2007-03-29
NO327798B1 (no) 2009-09-28
YU72001A (sh) 2004-07-15
DE60024431D1 (en) 2006-01-05
JP2002542230A (ja) 2002-12-10
HRP20010744B1 (en) 2010-08-31
SK287175B6 (sk) 2010-02-08
ATE311364T1 (de) 2005-12-15
DK1173418T3 (da) 2006-04-10
CN1354744A (zh) 2002-06-19
MXPA01010275A (es) 2003-07-21
AR023479A1 (es) 2002-09-04
MEP55708A (en) 2011-05-10
CA2370388A1 (en) 2000-10-26
KR20010109355A (ko) 2001-12-08
RU2235089C2 (ru) 2004-08-27
CA2370388C (en) 2009-10-13
EP1637519A1 (de) 2006-03-22
HRP20010744A2 (en) 2003-04-30
HK1046270A1 (en) 2003-01-03
ES2251996T3 (es) 2006-05-16
CZ20013672A3 (cs) 2002-01-16
HK1046270B (zh) 2005-03-11
NO20015014D0 (no) 2001-10-15
PL351245A1 (en) 2003-04-07
US6723751B1 (en) 2004-04-20
EP1173418B1 (de) 2005-11-30
CN1168712C (zh) 2004-09-29
EP1637519B1 (de) 2008-11-12
IL145921A0 (en) 2002-07-25
EP1173418A1 (de) 2002-01-23
WO2000063167A1 (en) 2000-10-26
AU773246B2 (en) 2004-05-20
DE60040811D1 (de) 2008-12-24
BR0010658A (pt) 2002-02-19
TR200501142T2 (tr) 2005-08-22
RS50916B (sr) 2010-08-31
CZ302459B6 (cs) 2011-06-01
MY122588A (en) 2006-04-29
ZA200108400B (en) 2003-04-30
IL145921A (en) 2006-07-05
HUP0200791A2 (hu) 2002-07-29
TWI276622B (en) 2007-03-21
DE19917233A1 (de) 2000-10-19
HUP0200791A3 (en) 2005-04-28
JP4662640B2 (ja) 2011-03-30
AU4542800A (en) 2000-11-02
SI1173418T1 (sl) 2006-02-28
PL203809B1 (pl) 2009-11-30
NO20015014L (no) 2001-10-15
SK14582001A3 (sk) 2002-01-07
TR200102993T2 (tr) 2002-03-21
HU229082B1 (hu) 2013-07-29

Similar Documents

Publication Publication Date Title
DE69811892D1 (de) Kristalline form von omeprazol-natriumsalz
DE60004317D1 (de) Salze von Sulfonium-Verbindungen
ATE353891T1 (de) Ditosylatsalze von chinazolinverbindungen
EE200300001A (et) Perindopriili tert-butüülamiinsoola kristallilinealfa-vorm
NO20016319D0 (no) VLA-4 inhibitor-forbindelser
ATE236899T1 (de) Neue kristallinische form des kaliumsalzes des (s)-omeprazols
DE69937455D1 (de) Cyano-substituierte amidsalze
ATE391502T1 (de) Kristalline formen von fluvastatin-natrium
NO20020030L (no) Krystallinske 1-metylkarbapenemforbindelser
DE60107074D1 (de) Kristallin form ii von cabergolin
NO20021525L (no) Polymorft salt
ATE339438T1 (de) Substanziell kristalline form von melagatran
ID27766A (id) Garam-garam paroksetin
EE200100381A (et) Morfolinobensamiidi uued soolad
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
ATE414059T1 (de) Kristalline form des natriumsalzes von 5-chlor-2- methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid
PT1175417E (pt) Compostos substituidos de benzolactamas
DE69940563D1 (de) Wachstum von aluminium-einkristallen
DK1224179T3 (da) Natrium-hydrogen-udbytter type 1-inhibitorkrystaller
ID26940A (id) Garam fosfat isopropil-metil-[2-(3-n-propoksifenoksi)-etil] amina
ID25793A (id) Garam-garam paroksetin
UA3653S (uk) Комплект етикеток для упакування солі
SE0004749D0 (sv) New salt form
SE0004748D0 (sv) New salt form
SE9904417D0 (sv) Crystalline form

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties